Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19448820 | 1.00 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL29583989 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL18879529 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23069352 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23243950 | 0.99 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17278377 | 0.94 | LMNA (0.69) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL21331976 | 0.94 | LMNA (0.69) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL21574298 | 0.94 | LMNA (0.69) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17267273 | 0.94 | LMNA (0.69) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23243955 | 0.94 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132845-A1 | GALNAC PHOSPHORAMIDITES AND THEIR USES | SILENCE THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | SILENCE THERAPEUTICS GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11299738-B2 | Further novel oligonucleotide-ligand conjugates | SILENCE THERAPEUTICS GMBH (DE) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912993-B2 | Nucleic acid linked to a trivalent glycoconjugate | RNASE1, DERA, SNRPE | LMNA 1865/4885KMT2A 1594/4885POLB 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.